[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605812":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":21,"responsibleParty":48,"collaborators":50,"id":53,"slug":20,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":20,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":20,"maxAge":20,"enrollmentInfo":60,"targetDuration":20,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":76,"overallStatus":24,"whyStopped":20,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"First Ascent Biomedical Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"xDRIVE Profiling","EXPERIMENTAL","Patients will receive tumor profiling via xDRIVE Functional Precision Medicine and Artificial Intelligence analysis",[13],"Diagnostic Test: xDRIVE Tumor Profiling",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","xDRIVE Tumor Profiling","Patients and physicians will receive tumor profiling data via xDRIVE Functional Precision Medicine and Artificial Intelligence analysis. As this is a feasibility study, results will be returned to the physician and the physician may use the data to inform the next line of treatment.",[9],null,[22,41],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"First Ascent Biomedical","RECRUITING","Miami","Florida","33183","United States",{"type":30,"coordinates":31},"Point",[32,33],-80.19366,25.77427,{"lat":33,"lon":32},[36],{"name":37,"role":38,"phone":39,"phoneExt":20,"email":40},"Chandler Fox","CONTACT","757-634-7635","cfox@firstascentbio.com",{"facility":42,"status":43,"city":25,"state":26,"zip":44,"country":28,"cosmosGeoPoint":45,"geoPoint":47,"contacts":20},"Florida International University","ACTIVE_NOT_RECRUITING","33199",{"type":30,"coordinates":46},[32,33],{"lat":33,"lon":32},{"type":49,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[51],{"name":42,"class":52},"OTHER","100605812",false,"NCT07167381","xDRIVE for Florida-based Cancer Patients","xDRIVE Functional Precision Medicine + Artificial Intelligence Individualized Treatments for Florida-based Cancer Patients With Relapsed\u002F Refractory Cancers","Inclusion Criteria:\n\n* Patients with recurrent\u002Frefractory cancer patients up to age 18 (willing to sign assent if ages 7 - 17 years)\n* -OR- Patients with recurrent\u002Frefractory cancer ≥18 years of age.\n* Patients who have received at least one prior line of standard of care therapy.\n* Patients able to provide treatment and outcome information from previous line(s) of therapy.\n* Patients with sufficient health status to undergo cancer therapy, e.g., Eastern Cooperative Group (ECOG) performance status of 0, 1, or 2 for adult patients.\n* Patients who are scheduled for or have recently undergone a tumor biopsy, excision, or resection.\n* Patients willing to have a blood draw or buccal swab performed for matched normal material for comparison during tumor DNA profiling.\n\nExclusion Criteria:\n\n* Patients who do not have malignant tissue available and accessible, patients where the amount of excised malignant tissue is insufficient material for ex vivo drug testing and\u002For genetic profiling, defined as \\\u003C0.3g for resections or core\u002Ffine-needle biopsies not containing malignant tissue by pathology review, or insufficient malignant tissue in peripheral blood or bone marrow aspirate samples.\n* Patients with insufficient health indicators to undergo therapeutic intervention.","ALL",{"count":61,"type":62},210,"ESTIMATED","INTERVENTIONAL",[65],"NA","Through this study funded by the Florida Cancer Innovation Fund, First Ascent will demonstrate state-wide feasibility of providing xDRIVE Functional Precision Medicine + Artificial Intelligence platform by assessing patient clinical benefit and health economics impacts. As this is a feasibility study, results will be returned to the physician and the physician may use the data to inform the next line of treatment. The investigator will run a prospective single-arm feasibility study providing the xDRIVE FPM AI platform to n = 210+ cancer patients throughout the state of Florida, especially those from underserved populations (pediatric patients and patients in Black, Brown, Hispanic, and rural communities).",[68,69,70,71,72,73,74,75],"Cancer","Neoplams","Refractory","Recurrence","Leukaemia","Lymphoma","Solid Tumor Malignancies","Solid Cancers",[77,78],"Functional Precision Medicine","Artificial Intelligence","2026-05-17",{"date":81,"type":82},"2026-05-19","ACTUAL",{"date":84,"type":82},"2025-11-01",{"date":86,"type":62},"2027-04-01",{"name":5,"class":6},2]